Advertisement

Early disarticulation of a bioresorbable vascular scaffold: an underreported consequence of repeat imaging

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1

References

  1. 1.

    Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122(22):2301–12.

  2. 2.

    Nakazawa G, Finn AV, Vorpahl M, Ladich E, Kutys R, Balazs I, Kolodgie FD, Virmani R. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol. 2009;54(21):1924–31.

Download references

Author information

Correspondence to Nick E. J. West.

Ethics declarations

Conflict of interest

Dr. West has acted as a consultant for Abbott Vascular. Dr. Hoole has acted as a consultant for St. Jude Medical and Abbott Vascular. All other authors have no conflicts of interest to declare.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (MPG 140492 kb)

Supplementary material 1 (MPG 140492 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Giblett, J.P., Brown, A.J., Hoole, S.P. et al. Early disarticulation of a bioresorbable vascular scaffold: an underreported consequence of repeat imaging. Cardiovasc Interv and Ther 33, 175–177 (2018) doi:10.1007/s12928-017-0464-y

Download citation